Published in Diabetes Metab on September 01, 2006
Relationship between modified homeostasis model assessment/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China. Int J Ophthalmol (2014) 0.81
Ideal glycated hemoglobin cut-off points for screening diabetes and prediabetes in a Chinese population. J Diabetes Investig (2016) 0.75
High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care (1998) 3.94
Non-cardiovascular disease mortality and diabetes mellitus. Lancet (1997) 2.01
Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia (1989) 1.96
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Does energy intake underreporting involve all kinds of food or only specific food items? Results from the Fleurbaix Laventie Ville Santé (FLVS) study. Int J Obes Relat Metab Disord (2000) 1.78
Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia (2002) 1.55
Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab (2005) 1.44
The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab (2003) 1.44
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care (1996) 1.41
Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ (1993) 1.35
Determinants and nature of dietary underreporting in a free-living population: the Fleurbaix Laventie Ville Santé (FLVS) Study. Int J Obes Relat Metab Disord (1997) 1.30
Diabetes as a risk factor for sudden death. Lancet (1999) 1.27
The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia (1997) 1.25
The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol (1991) 1.22
Inappropriateness and variability of antibiotic prescription among French office-based physicians. J Clin Epidemiol (1998) 1.21
Trends in antimicrobial drug use in the community--France, 1981-1992. J Infect Dis (1998) 1.20
Trends in the prevalence of obesity in the French adult population between 1980 and 1991. Int J Obes Relat Metab Disord (1999) 1.17
Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia (1991) 1.17
Reproducibility of HbA1c in a healthy adult population: the Telecom Study. Diabetes Care (1999) 1.12
A review of the metabolic syndrome. Diabetes Metab (2007) 1.12
Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia (2006) 1.10
High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol (1998) 1.08
Revision of diagnostic criteria for diabetes. Lancet (1996) 1.08
Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. Int J Epidemiol (2005) 1.03
Imprecision of new criteria for the oral glucose tolerance test. Diabetologia (1983) 1.02
Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab (2000) 1.00
Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care (2001) 1.00
Is insulin an independent risk factor for hypertension? The Paris Prospective Study. Int J Epidemiol (1997) 1.00
High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol (2001) 0.99
Comparison of glycosylated hemoglobin and fasting plasma glucose with two-hour post-load plasma glucose in the detection of diabetes mellitus. Am J Epidemiol (1985) 0.99
Macronutrient energy intake and adiposity in non obese prepubertal children aged 5-11 y (the Fleurbaix Laventie Ville Santé Study). Int J Obes Relat Metab Disord (2000) 0.98
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care (1998) 0.90
Relationships between abdominal body fat distribution and cardiovascular risk factors: an explanation for women's healthier cardiovascular risk profile. The D.E.S.I.R. Study. Int J Obes Relat Metab Disord (1999) 0.90
French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab (2008) 0.89
Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab (2005) 0.89
Obesity morbidity and health care costs in France: an analysis of the 1991-1992 Medical Care Household Survey. Int J Obes Relat Metab Disord (2000) 0.88
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev (2000) 0.87
Trends in aspirin, paracetamol and non-steroidal anti-inflammatory drug use in children between 1981 and 1992 in France. Eur J Clin Pharmacol (1998) 0.87
Upper-body fat distribution: a hyperinsulinemia-independent predictor of coronary heart disease mortality. The Paris Prospective Study. Arterioscler Thromb (1992) 0.87
Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ (1998) 0.87
Infant-feeding patterns are related to blood cholesterol concentration in prepubertal children aged 5-11 y: the Fleurbaix-Laventie Ville Santé study. Eur J Clin Nutr (2000) 0.86
[Medical resources consumption of type 2 diabetics in France in 1998]. Diabetes Metab (2000) 0.86
Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia (1992) 0.85
Agreement and discrepancy in the evaluation of normal and diabetic oral glucose tolerance test. Diabetes (1975) 0.85
Re: "A prospective population-based study of alcohol use and non-insulin-dependent diabetes mellitus". Am J Epidemiol (1991) 0.85
[Controlled cooperative trial of secondary prevention of cerebral ischemic accidents caused by atherosclerosis, using aspirin and dipyridamole]. Presse Med (1983) 0.84
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol (1990) 0.83
Prevalence of macrovascular complications and cardiovascular risk factors in people treated for diabetes and living in France: the ENTRED study 2001. Diabetes Metab (2008) 0.83
Cardiovascular and alcohol-related deaths in abnormal glucose tolerant and diabetic subjects. Diabetologia (1992) 0.82
Diabetic retinopathy, duration of diabetes and risk factors of atherosclerotic cardiovascular disease. Acta Diabetol Lat (1976) 0.81
Fibrinogen: a possible link between alcohol consumption and cardiovascular disease? DESIR Study Group. Arterioscler Thromb Vasc Biol (1999) 0.81
Evidence for distinct effects of GH and IGF-I in the metabolic syndrome. Diabet Med (2007) 0.81
Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obes Metab (1999) 0.81
The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001-2006 ENTRED cohort. Diabet Med (2014) 0.80
Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes Obes Metab (2004) 0.79
Insulin-resistance, hypertriglyceridaemia and cardiovascular risk: the Paris Prospective Study. Diabete Metab (1991) 0.78
Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the "SYMFONIE" study. Diabetes Metab (2006) 0.78
Prevention of type 2 diabetes: role of metformin. Drugs (1999) 0.78
Repeatability of the oral glucose tolerance test for the diagnosis of impaired glucose tolerance and diabetes mellitus. Diabetologia (1991) 0.77
Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia (2002) 0.77
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study]. Ann Endocrinol (Paris) (2008) 0.76
Pancreatic cancer and diabetes. N Engl J Med (1994) 0.75
High death rate from neoplasms in French diabetic and non-diabetic men. Lancet (1998) 0.75
Fasting blood glucose and risk of cardiovascular disease. Diabetes Care (1999) 0.75
BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metab (1991) 0.75
Prevalence of non-insulin dependent diabetes as perceived by general practitioners in France. Rev Epidemiol Sante Publique (1995) 0.75
Trends in antihypertensive drug use among orally treated diabetic patients, in France between 1981 and 1992. Impact of guidelines and new drugs. Diabetes Metab (2001) 0.75
[Diagnosis and evaluation of educational strategies for non-insulin-dependent diabetics and their treating physicians in France]. Journ Annu Diabetol Hotel Dieu (1991) 0.75
The relationship between behavioural pattern, overall and central adiposity in a population of healthy French men. Int J Obes Relat Metab Disord (1993) 0.75
[Totally reimbursed care for type 2 diabetes in 1994: characteristics and follow-up]. Diabetes Metab (2000) 0.75
Epidemiological analysis of patients with Type 2 diabetes in France. J Diabetes Complications (2001) 0.75
[Development of pharmaco-epidemiology in France]. Presse Med (1999) 0.75
Estimation of the prevalence of orally treated diabetes in France using a pharmacoepidemiologic approach: comparison between 1981 and 1992. Pharmacoepidemiol Drug Saf (1999) 0.75
Microalbuminuria and markers of the atherosclerotic process: the D.E. S.I.R. study. Atherosclerosis (2001) 0.75
[Vascular complications of diabetes: is there a glycemic threshold?]. Rev Prat (2001) 0.75
[Weight change, cardiometabolic risk and the impact of antidiabetic medications in type 2 diabetic patients]. Ann Cardiol Angeiol (Paris) (2010) 0.75
[Non-insulin-dependent diabetes in populations at risk: the Pima Indians]. Diabetes Metab (1997) 0.75
[Pharmacoepidemiology of diabetes: assessment of good use of oral antidiabetic drugs]. Diabetes Metab (2000) 0.75
[Placebo effect. Definition, observation conditions]. Rev Prat (1991) 0.75
[Contribution of data of efficacy trials to judge the improvement of the medical usefulness of a drug]. Therapie (1992) 0.75